Thursday, October 22, 2009

Cisplatin is the most active of chemo drugs tested for TNBC

Lab tests using cisplatin, doxorubicin, cyclophosphamide (4HC), and docetaxel against breast tumors showed that cisplatin was most effective against triple negative cancers. In research presented at the 2009 Breast Cancer Symposium of the American Society of Clinical Oncologists:

• ER- breast cancer is more sensitive to cisplatin than ER+ breast cancer.

• Her2- is slightly more sensitive than Her2+

• ER- /Her2- breast cancer is more sensitive than ER-/Her2+.

So, if you add up the negatives, that means that triple negative gets a special boost from cisplatin.

Researchers also noted that breast tumors defined as “poorly-differentiated” are more sensitive to cisplatin than moderate and well- differentiated tumors

The researchers’ conclusion: “Cisplatin is the most active of the four tested drugs in TNBC.”


Wednesday, October 21, 2009

Lip Gloss Helps TNBC research

Perk up your lips and help with breast cancer research--20 percent of the sales Sealed With a Cure lip gloss will go to triple negative research. A product of the Triple Negative Foundation and Purple Lab Cosmetics, the gloss is made of healthy ingredients like mangosteen and echinacea, and is paraben-free.

Friday, October 16, 2009

Vanderbilt Gets $4.7 Million for Triple-Negative Research

From Vanderbilt Medical Center's Weekly Newspaper:

Researchers at Vanderbilt University Medical Center have received a two-year, $4.7 million “Grand Opportunities” stimulus grant from the National Institutes of Health to launch a ground-breaking cancer drug discovery program.


The Vanderbilt Molecular Target Discovery and Development Center, a joint effort of the Vanderbilt Institute of Chemical Biology (VICB) and the Vanderbilt-Ingram Cancer Center, initially will hone in on “triple-negative” breast cancer, a particularly deadly form of the disease.


Researchers will try to identify genes that are the “drivers” for the different subtypes of triple-negative breast cancer, and then fashion drugs to block the action of the proteins encoded by the genes, with the intent of killing the cancer cells.


“The beauty of this approach is that if you end up with drugs at the end of this whole process, you already know which patients should get them,” said VICB director Lawrence Marnett, Ph.D., and the grant's principal investigator. More.



Monday, October 12, 2009

More on Vitamin D: Does it Help Prevent Breast Cancer?

Studies have been inconsistent in finding a relationship between Vitamin D and breast cancer. Now, recent research continues this ambiguity. A study published in the journal Breast Cancer Research in August 2009 found no association between postmenopausal breast cancer risk and levels of Vitamin D, regardless of hormone receptor status, body mass index, postmenopausal hormone therapy, weight gain, season of the year, or calcium intake.

However, researchers did note that:

• the source of Vitamin D might be important, with women who get the vitamin through their diet—in fortified milk or fish, for example—having higher levels circulating in their bodies. Also, dietary Vitamin D is strongly correlated with calcium, which may be effective in fighting breast cancer.

• Women living at northern latitudes—above 37° —get less Vitamin D from the sun and were more likely to have breast cancer than those in southern latitudes. This, however, could be due to chance, researchers say.

Of three previously published studies, two found a relationship between Vitamin D and breast cancer:

• An analysis of 701 cases from the Nurses' Health Study found a 27 percent lower relative risk of breast cancer in women with higher levels of Vitamin D.

• An analysis from the National Health and Nutrition Examination Survey (NHANES) reported a relative risk for fatal breast cancer among women with low levels of Vitamin D.

• Among 1005 postmenopausal cases in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, no association was found between Vitamin D and breast cancer risk.

So, what do we make of this? My conclusion: There is no risk found in taking Vitamin D, so let's make it part of our diet. If there is a chance it helps, why not take it? Dietary sources are better than supplements. The National Institute of Health provides an overview of Vitamin D and provides a list of its sources. The best source: cod liver oil. Sure, it tastes icky, but breast cancer is no picnic either.

NOTE, this study used the terminology serum 25-hydroxyvitamin D (25(OH)D or, simplified, 25(OH)D. For clarification of this terminology, check out the Medline Plus Encyclopedia. Basically, the terms refer to the blood test that measures levels of Vitamin D in the blood. The normal range is 30 to 74 nanograms per milliliter.

Sunday, October 11, 2009

Race Not a Factor in Pathologically Complete Response

According to researchers at the M.D. Anderson Cancer Center, pathologically complete response (PCR) is a primary factor for cancer survival, regardless of race.

The study consisted of 2,074 patients diagnosed with Stages II and III breast cancer who were treated at the M.D. Anderson between 1994 and 2008. Of these:

• 1,334 (64.3 percent) were white, with a 12.3 percent PCR.

• 302 (14.6 percent) black, with a 12.5 percent PCR.

• 316 (15.2 percent) Hispanic, with a 14.23 percent PCR.

• 122 (5.9 percent) "other" race groups, with a 11.5 percent PCR.

The median age was 50. All received neoadjuvant—before surgery—anthracycline- and taxane-based chemotherapy.

At a follow-up of 30 months, there were 438 recurrences and 327 deaths. The recurrence-free survival (RFS) and overall survival (OS) rates were:

• 71percent and 79 percent in whites.

• 60 percent and 57 percent in blacks

• 76 percent and 79 percent in Hispanics

• 75 percent and 84 percent in "other.”

"Our findings confirm pathological complete response is a strong prognostic indicator and a surrogate for good survival, despite a patient's race, and that it's vital we continue to strive towards achieving this milestone for all women with breast cancer," said Mariana Chavez MacGregor, M.D., a medical oncology fellow at M. D. Anderson. "The study also mandates that we continue to research the differences across races in breast cancer."

Read the complete news release here.


Support Breast Cancer Research and Win Great Stuff

Looking for a special way to celebrate your disease-free survival? Or a plain old birthday or anniversary? How about five days at an eco-lodge in Ecuador for two? Or a Namibia Safari trip? Bid on anything from a survivor necklace to a handbag, a Nextar GPS, or a set a soy candles in the breastcancer.org online auction. Support breast cancer research and get the chance to win great goodies. Bidding closes October 25 at 8 p.m.

Drug Significantly Reduces Triple Negative Brain Metastases in Mice

The drug Vorinostat prevented the formation of brain metastases of triple negative breast cancer in mice by 62 percent, according to research in the September 29 journal Clinical Cancer Research. The drug crosses the blood-brain barrier, which in the past has been a literal wall to drugs entering the brain, making brain cancer largely untreatable. According to the study’s researchers, from the Center for Cancer Research at the National Cancer Institute, Vorinostat works on both strands of the cancer DNA, slowing the rate of tumor growth. They suggest that it might be an effective cancer fighter in combination with other drugs or radiation.

Source: Palmieri D, Lockman PR, et al. Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks. Clin Cancer Res. Sept. 29, 2009. Vol.15, No. 19.


Register for Des Moines' Race for the Cure

Des Moines' Susan G. Komen Race for the Cure:

October 24, 2009, Iowa Capitol Grounds.

Register here.

Federal Stimulus Money Goes to Triple Negative Research

University of Chicago researchers have been awarded $800,000 from federal stimulus funds for a clinical study on treatment of triple-negative breast cancer. The award is part of $5 million in nationwide grants.

Tuesday, September 22, 2009

Diabetes Drug Could Be Effective in Fighting Triple Negative

The diabetes drug metformin, used in conjunction with the chemo drug doxorubicin, effectively eliminated cancer stem cells in laboratory tests at the Harvard Medical School, according to research published online September 14 in the journal Cancer Research. Cancer stem cells are thought to initiate tumors; they are resistant to standard cancer treatment.

Researchers studied four genetically different cancer types, including triple negative, and determined that the drug combination eliminated existing tumors and prevented regrowth; neither drug alone was effective against the cancer cells.

As a result of this tests, clinical trials are being planned on the use of metformin and doxorubicin in women with early stage breast cancer. Enrollment of patients may begin next year.

Source: Hirsch, Heather A., Iliopoulos, Dimitrios, Tsichlis, Philip N., Struhl, Kevin
Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission
Cancer Res 2009 0: 0008-5472.CAN-09-2994


Friday, September 11, 2009

PARP Inhibitors: A Personal Story about TNBC

Sharon Price tells her story of how PARP inhibitors and chemo have helped her survive triple-negative breast cancer that spread to her lungs. Watch it here, on WAVY-TV in Norfolk, VA.

Thursday, August 27, 2009

Is there a link between triple negative and inflammatory breast cancers?

A reader recently asked me about the connection between IBC and triple negative breast cancer (estrogen-receptor-negative, progesterone-receptor negative, and Her2-negative). The results are mixed.

According to the Inflammatory Breast Cancer Research Foundation, most cases of IBC are also triple negative, although I could find no citations to support that claim.

In recent research through the American Society of Clinical Oncology on women with TNBC, 12 percent of the women with TNBC also had IBC.

But, in a study in the journal The Breast 52 percent of the women with IBC were Her2 positive, which means they cannot be triple negative, as Her2-negative is the third part of that triplet. That leaves 48 percent who were Her2-negative, but they could have been any mix of estrogen and progesterone negatives and positive.

So, once again, the answer is that cancer is not one disease and may be as unique as out DNA. So, while there may be some connections between IBC and TNBC, it does not look like the two are inevitably linked.

Inflammatory breast cancer (IBC) can be difficult to diagnose, as it may show no obvious tumors. Its symptoms can seem like mastitis and some doctors may not recognize it as cancer. Instead, they prescribe antibiotics. Young women who are nursing can be at risk and should be aware that breast problems should be taken seriously.

The National Cancer Institute has a good overview of IBC.

I have had two good friends whose diagnosis of IBC required them to virtually force their doctors' hands to have them tested. Both are smart, professional woman. One is a doctor herself. Yet their doctors did not take their symptoms seriously. Both were finally diagnosed and, because they lost so much time arguing with their doctors, their cancers were advanced and required aggressive treatment. The great news: Both are healthy and cancer-free. One is 11 years past diagnosis, and one is five years out. The first had both breasts removed. The second had aggressive chemo.

Tuesday, August 25, 2009

Tamoxifen leads to increased risk of hormone-negative breast cancer

Even though I had estrogen-negative (ER-)  breast cancer, my oncologist was insistent that I take tamoxifen.  I refused.  And I changed oncologists. The research below supports my decision.   

Women who took tamoxifen for at least five years had more than a four-fold increased risk of estrogen-receptor negative cancer in the second breast compared to women who were not treated with hormone therapy, according to research published in the journal Cancer Research. 

The drug reduced the incidence of estrogen-receptor-positive breast cancer by 60 percent, however.

Researchers studied 367 women with estrogen-receptor-positive cancer that had also spread to the second cancer.  The comparison group was 728 women with only a primary cancer.

Some  details:

• breast cancer survivors overall who took hormonal therapy were at a reduced risk of second breast cancer.

• use of tamoxifen for at least five years reduced the risk of both estrogen-positive  and progesterone-positive breast cancer.

• use of the drug for at least five years led to increased risk of both estrogen-negative  and progesterone-negative. 

Researchers said that the reason the risk increases with longer exposure is because more time is needed  “to foster an environment that promotes estrogen receptor-negative tumor growth.”   Essentially, they said, hormone therapy gives hormone--negative cells a growth advantage.

 

SOURCE: Li, Christopher I., Daling, Janet R., Porter, Peggy L., Tang, Mei-Tzu C., Malone, Kathleen E., “Adjuvant Hormonal Therapy for Breast Cancer and Risk of Hormone Receptor-Specific Subtypes of Contralateral Breast Cancer,”  Cancer Research, 2009 0: 0008-5472.CAN-09-1355. Published online August 25, 2009. 

 

 

Monday, August 24, 2009

Alternative Treatments Can Supplement Breast Cancer Care

As I have mentioned before, alternative treatments have been important to me in my battle with breast cancer—during and after treatment. I have to give a nod to Western medicine—research consistently shows the chemo is especially effective in combating hormone-negative breast cancer, including triple negative. l

But yoga, meditation, acupuncture, and proper diet have been equally important, maybe more so. Here’s what I have done to supplement Western treatments of surgery, chemo, and radiation.

Yoga: I am a late-comer to this wonderful Eastern practice. I began doing yoga after I finished treatment and I try to do it at least four times weekly. Before cancer (BC), I used to love my evening drink—or drinks. I needed them to relax me. No more. One yoga session relaxes me way more than alcohol ever did—and the benefits continue, whereas alcohol-induced relaxation turns to nervousness and sleeplessness. And alcohol is implicated in cancer. So if yoga does nothing more than reduce my drinking, it has provided a serious benefit. But it does much more—it’s kept my body, I think, in shape internally and externally.

Meditation. Closely tied to yoga, meditation calms me, helps me think clearly and focus, makes me sleep better, and in general gives me a flat-out Zen feeling. Ahmmmmmmmmm. I am especially sensitive to noise. Now, after meditation, if I hear a bothersome noise—a neighbor’s stereo, for example—I breathe deeply into the noise and eventually I am calmed.

Acupuncture. My acupuncturist is a wonder. I went to her before each chemotherapy session and she prepared me well and, I believe, reduced my nausea. Now, she has a perceptive link to my health that truly balances me. I can walk into Abby’s office feeling internally whacky and leave feeling truly connected to my health. I have gone to her for allergies, poison ivy, lingering colds, and anything else that has not responded to my normal ministrations. When she listens to my pulse, she hears everything from the fact that I have recently eaten nuts and not chewed them thoroughly enough to the stomach upset I hadn’t yet mentioned. I believe that, if I had a serious health problem, she would be plugged into it before I was.

Proper diet. A low-fat diet rich in vegetables and fruits has been found to be a solid cancer fighter. I start every day with a green drink and, usually, a smoothie with organic yogurt, blueberries, freshly ground flax seeds, and a banana. I end every day with a mixture of freshly juiced carrots, kale, cabbage, parsley and, occasionally, a beet. Throughout the day I get my minimum of five servings of fruits and vegetables and focus on antioxidants (blueberries) and cruciferous cancer-fighters (kale, cabbage, broccoli). I make sure I get enough Vitamin D--preferably through sun, and folic acid through vegetables and supplements.

The benefit to this diet is that my body mass index is at a healthy 23. Before cancer, I was at 29, just a snip under being obese.

Breastcancer.org has a good discussion on complementary and alternative treatments.

Sunday, August 23, 2009

Italian trials show success with PET adjuvant therapy

American and European chemotherapy treatments use different drugs. So when I read about research done in Italy that showed significant response to a battery of chemo drugs, I was curious. The more I read about the study, though, the more I wondered. Look at the drugs used below. That’s a lot. A whole lot. Still, the response is good. But the toxic reactions are also significant.

Here’s the scoop:

Eight weekly cycles of cisplatin, epirubicin, and paclitaxel (PET) before surgery showed improvement in disease-free survival for women with triple negative breast cancer, in a phase II trial of women studied from 1999 through 2008. All had large ER-, PR-, Her2- tumors.

Seventy-four women received cisplatin (30 mg/m2) , (epirubicin 50 mg/m2), paclitaxel (Taxol) (120 mg/m2), with granulocyte colony-stimulating factor support. Within three weeks of chemo, all had surgery, primarily breast-conserving surgery. Forty-six of the women were in complete remission after surgery.

After that, those with fewer than four affected lymph nodes had combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil. Those with more than four affected nodes had an additional four cycles of fluorouracil-epirubicin-cyclophosphamide (FEC) (epirubicin instead of methotrexate)

Forty-six of the women had pathologically complete response (pCR)—their cancer was effectively gone—after this regimen.

At 41 months, five-years projected disease-free survival (DFS) was 90 percent for the pCR women. For those without a pCR, the five-year DFS was 57 percent.

The 90 percent number, of course, is great. Still, that’s a lot of chemo. And 31 of the patients had severe neutropenia and anemia. Fewer than 20 percent had severe non-hematological toxicity.

The study was published in the July 2009 Annals of Oncology.

For comparison, in the United States, the current therapy consists of high-doses of cytoxan and adriamycin (AC) every two weeks; taxol is added (ACT) for those with affected lymph nodes. This offers a five-year overall survival rate of 83 percent for hormone-negative and a five-year disease-free survival rate of 73 percent. This research was published in the Journal of the American Mecial Association in 2006.

ACT was also found to improve disease-free survival for triple negative in a study published in the Journal of Oncology in 2009.

Thursday, August 20, 2009

Karen Chiovaro 1956-2009

We lost another wonderful woman to triple negative breast cancer this week. Karen Chiovaro, my colleague and friend, died August 16. Karen was diagnosed in August 2007 and went through chemo and radiation, then breast reconstruction at the end of the process, in February 2008. The cancer returned shortly after that and she had aggressive chemo. My last email from her was her usual positive message, saying tests were good and that she was a candidate for PARP inhibitors. That was exactly a month before she died. PARP inhibitors do show great promise, but the research was a little too slow for Karen. Let’s support breast cancer research to encourage development of treatments for TNBC.

Karen was a vivacious woman with a true gift for life. She started her career as a school teacher, then moved into the production department at Meredith Corporation, where I met her. She ultimately became Senior Director of Production/Advertising for Meredith. Karen often visited my classes at Drake, walking students through an exercise in which they determined placement of pages in an actual magazine, usually Better Homes and Gardens.  It taught them a great deal about the relationship between advertising and editorial. She also was a valuable source, with her colleague Joanne Williams, on the production chapter of my magazine textbook, The Magazine from Cover to Cover.  And, in the brief period between treatment and remission, she even came to Drake to help interview staff members for the first issue of Think magazine, offering valuable expertise to the student who became production editor.

Karen’s obituary is here.

I will miss her.



Sunday, August 16, 2009

Cancer Survivors: Get Behind Healthcare Reform

If I were looking for insurance right now, I would be largely out of luck. As a breast cancer survivor, I have that nasty pre-existing condition that allows insurers to deny me coverage or charge me so much I cannot afford it. When I turn 65, however, I will be eligible for Medicare, with no restrictions because of previous health problems. I will pay the same as other Medicare recipients for my care. Even Medigap policies—supplemental insurance that covers the 20 percent of health costs not covered by Medicare—cannot discriminate based on pre-existing coverage.


That, to me, is the biggest reason cancer survivors, their families and loved ones should support healthcare reform and should not be afraid of any expansion of government-run plans. At present, government-run healthcare allows us the treatment we need and views us as whole persons rather than pariahs who had the gall to get sick. Insurance companies too often look at us as expensive inconveniences. It is unconscionable that, in America, sick people go broke trying to pay for care or avoid needed treatments because their insurance won’t cover them. This is not the healthcare a great country deserves; it is the healthcare the insurance companies allow us to have.


Among the basic tenets of President Obama’s plan are the necessity of covering pre-existing conditions, protecting families from healthcare-related bankruptcy, and allowing people to maintain coverage if they lose their jobs. These are all essential to anybody who has had any type of cancer diagnosis. That big “C” can easily translate into a big “No” from big insurance.


The American Cancer Society supports healthcare reform for these reasons and for another biggee—prevention. The cost of a mammogram can cause a cash-strapped women to avoid caring for her health, which can put her life in jeopardy. In what world is that considered right?


DEATH PANELS

Aurghhhhhhhhh. It’s startling that this idea has gained the traction is has. The healthcare bill as it exists simply states that people have the option of end-of-life counseling. The word option means we can take it or leave it. And this means only things like living wills or an explanation of Hospice care. My husband and I already have living wills—we got them before I even got sick. We do not want to be kept on life support if our lives are essentially over—and we do not want our kids burdened with that decision.


Interestingly, Republicans supported this option in the 2003 Medicare prescription drug bill. Now, they are ranting about pulling the plug on Grandma. Is that politics or principle? Well....


One conservative, however, David Brooks of The New York Times, said, on today’s Meet the Press, "the crazies are attacking the plan because it will cut off granny. That is simply not true, that simply is not going to happen." On Friday, on PBS’s News Hour, Brooks said, “But it's about having serious discussions about care at the end of life. And we're going to have to have those discussions. So, in some weird way, I'm pro-death panel. I want to have those discussions, whether it's one-on-one or just as a society."


Be assured that death panels are not going to come to the chemo ward and tell us we’re all useless and not fit to live. A wise doctor, however, might give us some counseling about how to face the end of life. Death is going to happen to all of us, although most people avoid even thinking about it. Once you’ve had cancer, though, the reality of death is embedded in your consciousness. Still, are we really ready to face it? Do we know what Hospice offers? Do we understand what a living will is and what it means? Have we made provisions that mean we accept the responsibility for what happens at the end of our lives, rather than foisting that on our children or grandchildren?


Healthcare reform, as I see it, is about fairness. I am more invested, I suspect, because of the many people I know struggling with cancer. Fighting the disease is enough. We should not also have to fight our insurance companies. Let's level the playing field and truly give patients the rights they need and deserve.

Friday, August 14, 2009

Is HRT safe after a triple-negative breast cancer diagnosis?

I got a question from a reader about taking hormone replacement therapy after a triple-negative breast cancer diagnosis—she is five years post-diagnosis disease free. (Yea for her.) I cannot find any research on this specific issue, but I did find a few related studies. Some of you might have similar questions, so I am posting this for others who might be in this situation.

• Some cases of HR- recur as HR+. Research on this was published in the Annals of Oncology. It was a pretty small sample, though—only 40 women initially.

• Estrogen can be a factor in the earliest formation of hormone-negative disease, according to research in the Journal of Steroid Biochemistry and Molecular Biology.

• The association between HRT use and breast cancer was the same for TNBC as for other forms of breast cancer in another study in the Annals of Oncology.

• Oral contraceptives were associated with a higher risk of TNBC in a study published in the journal Cancer Epidemiology, Biomarkers and Prevention.

I would suggest trying alternative treatments such as acupuncture, yoga, and meditation. Also, watch your diet--eat lots of vegetables and fruit, reduce fats, processed carbs (sugar, white flour), caffeine, and alcohol. These will also help you fight cancer--an added bonus--and lose weight, which can reduce menopausal symptoms. Also, make sure you get enough calcium and vitamin D. I had success with evening primrose for hot flashes.

Friday, July 31, 2009

Cancer antigen tested as potential vaccine for hormone- negative breast cancer

Scientists have found that one specific cancer antigen—CT-X—is more frequently found in hormone receptor-negative breast cancer than in other types of breast tumors, according to research published online in advance of publication in Proceedings of the National Academy of Sciences.

And this means?

Ultimately, researchers say, vaccines based on CT-X might provide treatment for ER-negative patients. 

Whooheee.  Keep the research coming.  And let's turn it into treatment options.


SOURCE: Anita Grigoriadis, Otavia L. Caballero, Keith S. Hoek, Leonard da Silva, Yao-Tseng Chen, Sandra J. Shin, Achim A. Jungbluth, Lance D. Miller, David Clouston, Jonathan Cebon, Lloyd J. Old, Sunil R. Lakhani, Andrew J. G. Simpson, and A. Munro Neville. "CT-X antigen expression in human breast cancer," Proceedings of the National Academy of Sciences, 2009. www.pnas.org/cgi/doi/10.1073/pnas.0906840106 



Monday, July 27, 2009

New Vaccine Might Treat Hormone Negative Breast Cancers Such as TNBC

From the Ludwig Institute for Cancer Research:  Vaccine in Clinical Trials Shows Promise in Treating ER-Negative Breast Cancers, Including Triple Negative Breast Cancer: 


A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study—to be published in the Early Edition of the Proceedings of the National Academy of Sciences this week—was led by the international Ludwig Institute for Cancer Research (LICR). ER negative breast cancers, which account for a third of all breast cancer cases, are a group of tumors that has a generally poor prognosis and few therapy options. A subgroup of the ER negative group is triple-negative breast cancer (TNBC), which lacks the estrogen, progesterone and HER2 receptors. TNBC is responsible for most of the breast cancers that strike down African American and young women.


In the current study, gene and protein expression studies showed that nearly half of primary ER negative and triple-negative breast cancers express members of either or both the MAGEA and NY-ESO-1/CTAG1B families of CT-X genes. Approximately half of the primary tumor samples from patients with the basal-like form of breast cancer, which is usually ER negative, also expressed either or both of these gene families, and nearly two-thirds of metastases from basal-like tumors also expressed these genes.


These findings suggest that a therapeutic vaccine combining members of the two CT-X families could be a new therapy approach to filling a critical unmet need.


Dr. Andrew Simpson, LICR scientific director and an author of the study, said that clinical trials based on the findings of the PNAS study could theoretically be initiated in the near future. "Vaccines targeting MAGEA3 are already in phase III trials, and the Cancer Vaccine Collaborative, a partnership between the Ludwig Institute and the Cancer Research Institute, has demonstrated the safety of different forms of the NY-ESO-1 antigen in phase I and II trials in a variety of tumor types."


According to LICR's Dr. A. Munro Neville, the senior author of the study, obtaining clinic-grade material for more members of the CT-X families and funding for a clinical trial will be the next steps in determining if therapeutic cancer vaccines can meet a critical need in breast cancer therapy.


CT genes—the X denotes chromosome localization—encode CT antigens, proteins that are recognized by the immune system. Spontaneous immune responses against CT antigens are thought to be a natural form of cancer control and might be the mechanism behind spontaneous remission.


Therapeutic cancer vaccines are being developed to induce, strengthen and/or sustain immune responses against cancer. GlaxoSmithKline (GSK), which licensed MAGEA3 and NY-ESO-1 from LICR, is currently conducting phase III clinical trials of a MAGEA3-based cancer vaccine, or "antigen-specific cancer immunotherapy" (ASCI) in non-small cell lung cancer and melanoma.

Source: Ludwig Institute for Cancer Research